Outcomes of patients with esophageal and gastric cancer in Sri Lanka: A retrospective survival analysis

被引:0
作者
Wijesekera, Sidath [1 ,2 ]
Alagiyawanna, Lanka [1 ,2 ]
Peiris, Vimukthini [1 ,2 ]
Silva, Damitha Chathuranga [2 ]
Rupasinghe, Tiromi [1 ,2 ]
Balawardena, Jayantha [2 ,3 ]
Skandarajah, Thurairajah [1 ,2 ]
Jeyakumaran, Nadarajah [1 ,2 ]
Gunasekera, Dehan [1 ,2 ]
Bandusena, Minoli [2 ,4 ]
Joseph, Nuradh [2 ,5 ]
机构
[1] NCI, Sri Lanka Coll Oncologists, Dept Clin Oncol, Batticaloa, Sri Lanka
[2] Sri Lanka Coll Oncologists, Sri Lanka Canc Res Grp, Batticaloa, Sri Lanka
[3] Gen Sir John Kotalawela Def Univ Hosp, Deparment Clin Oncol, Boralesgamuwa, Sri Lanka
[4] Teaching Hosp, Dept Surg Oncol, Anuradhapura, Sri Lanka
[5] Teaching Hosp, Dept Clin Oncol, Batticaloa, Sri Lanka
关键词
Esophageal cancer; gastric cancer; real-world data; Sri Lanka; survival; ADENOCARCINOMA; CARCINOMA;
D O I
10.4103/jcrt.jcrt_817_21
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction:Esophageal carcinoma is the fourth most common cancer among males and sixth most common cancer among females in Sri Lanka. Gastric cancer is less common, but its incidence is gradually rising. We conducted a retrospective analysis of survival of esophageal and gastric cancer patients treated at National Cancer Institute, Maharagama, Sri Lanka. Methodology:Patients with esophageal and gastric cancer treated in three selected oncology units of the National Cancer Institute, Maharagama during 2015 and 2016 were included in the study. Data on clinical and pathological factors were extracted from clinical records. Overall survival (OS), defined as time to death or loss to follow-up, was the primary endpoint. Univariate and multivariate analyses of survival were performed using the log-rank test and Cox proportional-hazard model, respectively. Results:The study population comprised 374 patients with a median age of 62 years (interquartile range 55-70). Majority (64%) were male and had squamous cell carcinoma (58%). In the sample, 20% were gastric cancers, while 71% were esophageal cancers, and 9% had gastro-esophageal junction tumors. The 2-year OS was 19% in patients treated with curative intent (95% confidence interval [CI] 14-26 months) with those receiving neoadjuvant chemotherapy, followed by radical surgery having the highest survival (P < 0.001, hazard ratio 0.25 [95% CI 0.11-0.56]). Median OS was 2 months (95% CI 1-2 months) in patients treated with palliative intent. Conclusion:Our results suggest that the outcome of patients with esophageal and gastric cancer is poor in Sri Lanka. Early detection and greater utilization of multimodality treatment could improve outcomes of these patients.
引用
收藏
页码:S294 / S299
页数:7
相关论文
共 14 条
  • [1] Squamous cell carcinoma and adenocarcinoma of the lower third of the esophagus and gastric cardia: similarities and differences
    Alexandrou, A
    Davis, PA
    Law, S
    Murthy, S
    Whooley, BP
    Wong, J
    [J]. DISEASES OF THE ESOPHAGUS, 2002, 15 (04) : 290 - 295
  • [2] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Bang, Yung-Jue
    Van Cutsem, Eric
    Feyereislova, Andrea
    Chung, Hyun C.
    Shen, Lin
    Sawaki, Akira
    Lordick, Florian
    Ohtsu, Atsushi
    Omuro, Yasushi
    Satoh, Taroh
    Aprile, Giuseppe
    Kulikov, Evgeny
    Hill, Julie
    Lehle, Michaela
    Ruschoff, Josef
    Kang, Yoon-Koo
    [J]. LANCET, 2010, 376 (9742) : 687 - 697
  • [3] RISING INCIDENCE OF ADENOCARCINOMA OF THE ESOPHAGUS AND GASTRIC CARDIA
    BLOT, WJ
    DEVESA, SS
    KNELLER, RW
    FRAUMENI, JF
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (10): : 1287 - 1289
  • [4] Clinical Oncology in Sri Lanka: Embracing the Promise of the Future
    Joseph, Nuradh
    Gunasekera, Sanjeeva
    Ariyaratne, Yasantha
    Choudhury, Ananya
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (03): : 466 - 470
  • [5] Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
    Kang, Yoon-Koo
    Boku, Narikazu
    Satoh, Taroh
    Ryu, Min-Hee
    Chao, Yee
    Kato, Ken
    Chung, Hyun Cheol
    Chen, Jen-Shi
    Muro, Kei
    Kang, Won Ki
    Yeh, Kun-Huei
    Yoshikawa, Takaki
    Oh, Sang Cheul
    Bai, Li-Yuan
    Tamura, Takao
    Lee, Keun-Wook
    Hamamoto, Yasuo
    Kim, Jong Gwang
    Chin, Keisho
    Oh, Do-Youn
    Minashi, Keiko
    Cho, Jae Yong
    Tsuda, Masahiro
    Chen, Li-Tzong
    [J]. LANCET, 2017, 390 (10111) : 2461 - 2471
  • [6] Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Lordick, F.
    Mariette, C.
    Haustermans, K.
    Obermannova, R.
    Arnold, D.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 : v50 - v57
  • [7] Lucas E., 2011, Cancer Survival in Africa, Asia, the Caribbean and Central America
  • [8] National Cancer Control Programme Sri Lanka, 2021, Cancer Incidence Mortality Data Sri Lanka 2019
  • [9] National Institute for Health and Care Excellence, Oesophago-Gastric Cancer: Assessment and Management in Adults
  • [10] Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
    Shapiro, Joel
    Van Lanschot, J. Jan B.
    Hulshof, Maarten C. C. M.
    van Hagen, Pieter
    Henegouwen, Mark I. van Berge
    Wijnhoven, Bas P. L.
    van Laarhoven, Hanneke W. M.
    Nieuwenhuijzen, Grard A. P.
    Hospers, Geke A. P.
    Bonenkamp, Johannes J.
    Cuesta, Miguel A.
    Blaisse, Reinoud J. B.
    Busch, Olivier R. C.
    ten Kate, Fiebo J. W.
    Creemers, Geert-Jan M.
    Punt, Cornelis J. A.
    Plukker, John Th M.
    Verheul, Henk M. W.
    Bilgen, Ernst J. Spillenaar
    van Dekken, Herman
    van der Sangen, Maurice J. C.
    Rozema, Tom
    Biermann, Katharina
    Beukema, Jannet C.
    Piet, Anna H. M.
    van Rij, Caroline M.
    Reinders, Janny G.
    Tilanus, Hugo W.
    Steyerberg, Ewout W.
    van der Gaast, Ate
    [J]. LANCET ONCOLOGY, 2015, 16 (09) : 1090 - 1098